Related Experiment Video

Updated: Jun 27, 2025

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

1.9K

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in

Masayoshi Shinjoh1, Kanae Togo2, Tomoyuki Hayamizu2

  • 1Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.

Expert Review of Vaccines
|April 29, 2024
PubMed

Insights

The 20-valent pneumococcal conjugate vaccine (PCV20) is more cost-effective than the current 13-valent PCV13 vaccine for pediatric use in Japan. PCV20 offers greater health benefits and lower costs from both societal and healthcare payer perspectives.

Area of Science:

  • Health Economics
  • Vaccinology
  • Public Health

Background:

  • The Japanese National Immunization Program utilizes the 13-valent pneumococcal conjugate vaccine (PCV13) for pediatric immunization.
  • Pneumococcal infections pose a significant public health burden, necessitating ongoing evaluation of vaccine efficacy and cost-effectiveness.

Purpose of the Study:

  • To assess the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) compared to PCV13 in the Japanese pediatric population.
  • To determine the economic value of PCV20 in preventing pneumococcal diseases.

Main Methods:

  • A decision-analytic Markov model was employed to simulate health outcomes and costs over a ten-year period.
  • The analysis considered societal and healthcare payer perspectives.
  • Key outcomes included quality-adjusted life-years (QALYs), prevented cases, and deaths from invasive pneumococcal disease, pneumonia, and acute otitis media.

Main Results:

  • PCV20 demonstrated dominance over PCV13, being both less costly and more effective.
  • From a societal perspective, PCV20 yielded an additional 294,599 QALYs and reduced costs by JPY 352.6 billion.
  • From a payer perspective, PCV20 resulted in JPY 178.9 billion in savings and improved QALYs.

Conclusions:

  • PCV20 is a dominant strategy compared to PCV13 for pediatric immunization in Japan, irrespective of the perspective analyzed.
  • Sensitivity and threshold analyses confirmed the robustness of these findings, indicating PCV20's favorable cost-effectiveness profile.
Abstract

Keywords:
Cost-effectivenessJapanPCV20pneumococcal diseasevaccination

More Related Videos

Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children06:22

Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children

Published on: February 10, 2023

986
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.4K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
44.4K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
1.0K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.6K
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
157
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
69